共 65 条
[1]
Wahl B(2018)Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Infect Dis 18 1191-1210
[2]
O'Brien KL(2018)Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15 Lancet Glob Health 6 e744-e757
[3]
Greenbaum A(2021)A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006–2019) Expert Rev Vaccines 10 156-166
[4]
Wang BC(2015)Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines PLoS ONE 3 560-569
[5]
Chaiyakunapruk N(2014)Cost-effectiveness analysis of pneumococcal vaccination with the pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines Value Health Reg Issues 15 353-371
[6]
Zhu S(2021)Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®) Hum Vaccine Immunother 7 127-136
[7]
Haasis MA(2019)Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico Hum Vaccine Immunother 21 1765-1778
[8]
Ceria JA(2018)Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada Infect Dis Ther 10 909-918
[9]
Kulpeng W(2021)Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study Lancet Infect Dis 17 1162-1172
[10]
Teerawattananon Y(2021)Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium Infect Dis Ther 17 305-324